Ameriprise
FBRX

Ameriprise’s Forte Biosciences FBRX Stock Holding History

Ameriprise’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.9M Buy
418,891
+307,103
+275% +$7.28M ﹤0.01% 2135
2026
Q1 		$2.9M Sell
111,788
-41,239
-27% -$1.19M ﹤0.01% 2776
2025
Q4 		$4.17M Buy
153,027
+83,135
+119% +$1.46M ﹤0.01% 2567
2025
Q3 		$1.05M Buy
+69,892
New +$805K ﹤0.01% 3340

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ameriprise's FBRX Position: Q2 2026 in Review

Ameriprise increased its Forte Biosciences (FBRX) stake by 275% in Q2 2026, buying an estimated $7.28M and bringing the position to 418,891 shares worth $8.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2135.

Ameriprise first reported a position in FBRX in Q3 2025 and has held it in 4 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Ameriprise held 418,891 shares of Forte Biosciences worth $8.9M as of Q2 2026.
  • Ameriprise bought 307,103 Forte Biosciences shares in Q2 2026, an estimated $7.28M.
  • Forte Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2135 holding.
  • Ameriprise first reported a position in Forte Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.